Search Criteria Sample Clauses

Search Criteria. For the purposes of PROSO, we defined a case study as needing to satisfy the following criteria: A societal engagement initiative associated with research and innovation in the three domains of nanotechnology, food & health, and bioeconomy. This initiative must have taken place between 2011 and the present. It can be entirely publicly funded, or be a recipient of public-private funding. Societal engagement was defined as activities or initiatives that include Third Sector Organisations (TSOs, defined on page 3) and/or the general public. This criterion excludes initiatives such as public-private partnerships between a university and industry partners that do not involve TSOs or the public. This criterion also excludes research projects that only consist of social scientists working with natural scientists in research: TSOs and/or members of the public must be involved. Engagement was understood to denote an initiative or process that allows for (or at least is intended to allow for) genuine two-way interactions between participants. This criterion excluded initiatives and processes that were primarily targeted at informing and educating an audience. There had to be an indication that the initiative or process aims at gathering the perspectives, concerns or interests of participants and at inducing a dialogue between participants. This included situations that occurred in person, virtually (on the internet), or through a mobile app. For example, a video posted online that allowed comments from the public was not considered to be ‘engagement’ because 1) the focus is on the information being provided, 2) the comments expressed are not a dialogue between parties, and 3) they are not being used to inform any other processes. In the case of social science research, the methods used needed to be a true dialogue with TSOs and public stakeholders. There was a recognition that some situations could be difficult to differentiate, especially in the initial search stage, but if official communication focused solely on providing information the case should not be included. In ambiguous cases, the case was documented and doubts were noted (see Table 1).
AutoNDA by SimpleDocs
Search Criteria. If either party intends to employ an electronic search to assist with identifying potentially responsive documents, then the parties must, in good faith, attempt to reach an agreement without intervention of the Court as to the searches to be conducted, the data to be searched and the relevant time period for such searches. No later than the day a producing party produces documents, it shall identify to the requesting party, by email or other writing, the search terms it used. The requesting party shall identify by email challenges to that list, identifying specific search terms it believes should be searched or not searched, within three (3) business days after receiving the producing party’s terms. The parties will work in good faith to reach agreement on search terms within three (3) business days after receipt of the requesting party’s challenges.
Search Criteria. The search is intended to be performed at both work and manifestation metadata. Works can be searchable by the following metadata: • Title • Contributor(s) • Language of Text • ISTC (in the future when ISTC will be assigned to works) • ISNI (in the future when ISNI will be in place) To search at manifestation level it is necessary at least to add one of the following metadata: • ISBN • Publisher • Imprint • Country Of Publication Search modes Initially the system shall allow end users to perform single searches. According to different user needs that may arise during the ROW evolution the implementation of bulk searches is foreseen.
Search Criteria. Section 1(ff)(ii) is amended to delete the words “to Idearc”.

Related to Search Criteria

  • Selection Criteria Each Contract is secured by a new or used Motorcycle. No Contract has a Contract Rate less than 1.00%. Each Contract amortizes the amount financed over an original term no greater than 84 months (excluding periods of deferral of first payment). Each Contract has a Principal Balance of at least $500.00 as of the Cutoff Date.

  • Acceptance Criteria 6.7.2.1. During the test there shall be no evidence of:

  • Protocol No action to coerce or censor or penalize any negotiation participant shall be made or implied by any other member as a result of participation in the negotiation process.

  • Performance Criteria The Performance Criteria are set forth in Exhibit A to this Agreement.

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless it will suffer significant uncompensated economic or operational harm from the delay, (1) attainment of the same milestone has previously been delayed, or (2) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.

  • Regulatory Milestones Celgene shall make the following approval milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the Regulatory Milestone Events set forth below with respect to the first Co-Co Product that achieves such event. For clarity, each milestone set forth below shall be due and payable one time only (regardless of the number of Co-Co Products to achieve any such Regulatory Milestone Event). CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Regulatory Milestone Event (For the first Co-Co Product that achieves such event) Milestone Payments (in $ millions) [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] For each of Paragraphs (1) - (3) of this Exhibit C-2, the Parties understand and agree that in no event will more than one (1) milestone payment be paid with respect to any specific event triggering a payment under this Jounce Lead Co-Co Agreement.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Development and Regulatory Milestones With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Time is Money Join Law Insider Premium to draft better contracts faster.